Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech takes steps to protect Lucentis

Executive Summary

As of Nov. 30, Genentech will no longer allow compounding pharmacies to purchase its VEGF inhibitor Avastin from authorized wholesale distributors, the firm announces Oct. 11 in a letter to retinal physicians. The move is to prevent the off-label use of Avastin (bevacizumab), which is approved for oncologic uses, for wet age-related macular degeneration in place of Genentech's VEGF inhibitor Lucentis (ranibizumab), which is approved for AMD. Genentech's letter notes that "FDA raised concerns related to the sterility and repackaging of Avastin for ocular use in a warning letter to a compounding pharmacy and, separately, during a routine FDA inspection of our South San Francisco manufacturing facility, concerns were raised ... related to the ongoing ocular use of Avastin because it is not designed, manufactured or approved for this use." The National Eye Institute is running trials studying Avastin in ocular settings, including a head-to-head comparison with Lucentis in AMD (1"The Pink Sheet" April 16, 2007, p. 8)...

You may also be interested in...

Genentech Meets With Eye Groups Protesting Avastin Sales Restrictions

Eye doctors furious over Genentech's decision to halt sales of Avastin to compounding pharmacies have succeeded in grabbing the company's attention. On Oct. 26, three of Genentech's top officers, CEO Arthur Levinson, Chief Medical Officer Hal Barron, and president of product development, Susan Desmond-Hellmann, traveled to Washington, D.C. to meet with two physician groups

Lucentis Faces Additional Pressure From NIH’s Avastin Trials

Genentech could face difficulties enrolling trials for its ocular vascular endothelial growth factor inhibitor Lucentis due to pressure from NIH-sponsored trials of the firm's oncologic VEGF inhibitor Avastin

USP Nitrosamine Impurities Chapter Reflects Careful Coordination With US, EU Authorities

The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts